A5014960717- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS Research and Interventions
- Primary Care and Health Outcomes
- Vaccine Coverage and Hesitancy
- Public Health Policies and Education
- Homelessness and Social Issues
- Healthcare Systems and Reforms
- HIV, Drug Use, Sexual Risk
- Dental Research and COVID-19
- SARS-CoV-2 detection and testing
- Healthcare Policy and Management
- COVID-19 diagnosis using AI
- Chronic Disease Management Strategies
- Community Health and Development
- Food Security and Health in Diverse Populations
- Health disparities and outcomes
- COVID-19 Clinical Research Studies
- Emergency and Acute Care Studies
- COVID-19 Pandemic Impacts
- Diabetes Management and Education
- Global Public Health Policies and Epidemiology
- COVID-19 and healthcare impacts
The University of Melbourne
2015-2024
Peter Doherty Institute
2015-2024
Victorian Health Promotion Foundation
2017-2024
Murdoch Children's Research Institute
2023
Australian Centre for HIV and Hepatitis Virology Research
2021-2023
Victorian Infectious Diseases Reference Laboratory
2014-2023
The Royal Melbourne Hospital
2014-2020
Footscray Hospital
2017-2018
Melbourne Health
2017
Monash University
2017
The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In certain well defined groups the far greater, yet an estimated 27% people living with HBV remain undiagnosed. Appropriate screening improves detection, increases opportunity for treatment, and ultimately reduces significant morbidity mortality associated development liver fibrosis hepatocellular carcinoma (HCC).This statement highlights important aspects management Australia. There have been recent changes...
Background and Aims Chronic hepatitis B (CHB) is a significant global health concern, the most prevalent blood‐borne virus in Australia. World Health Organization (WHO) member states have committed to elimination, with targets diagnose 90% of people living CHB, treat 80% those eligible, reduce attributable deaths by 65% year 2030. Australia has national diagnosed, 20% on treatment, 30% reduction 2022. Approach Results We constructed implemented mathematical model estimate burden CHB...
To measure progress towards Australia's National Hepatitis B Strategy 2014-17 targets, and assess geographic variation in disease burden access to care for those living with chronic hepatitis (CHB).Data were generated from routinely collected sources, including risk-group prevalence population data, infectious diseases notifications, Medicare records, immunisation registry assessed nationally according area 2013-15.CHB 2015 was 239,167 (1.0%), 62% of affected having been diagnosed (target...
Summary Antiviral therapy for hepatitis B is effective and reduces the risk of progression to cirrhosis liver cancer but often required an indefinite duration. Treatment adherence important prevent development resistance optimize outcomes. Pharmacy measures can be used assess treatment adherence, with medication possession ratio being less susceptible bias than physician‐ or self‐reported adherence. The aim this study was measure in public hospital outpatients over a 3‐year period examine...
Risk-based testing is failing one-third of people living with chronic hepatitis B in Australia The United States Preventive Services Task Force recently issued new guidance that all adults aged 18–79 years should be offered screening for C virus infection,1 expanding on prior risk- and age-based recommendations. rationale infection a common condition (estimated 1% prevalence) leading to an increasing burden disease from cirrhosis liver cancer, it easy test for, there are well tolerated...
Investigate the cascade of care for chronic hepatitis B (CHB) and estimate impacts increasing treatment uptake on attributable burden, according to jurisdiction.A mathematical model CHB in Australia was utilised, combined with notifiable disease Medicare data. We estimated proportion who were diagnosed, engaged receiving each state/territory, projected future mortality.The highest all measures New South Wales, however, largest increase over time occurred Northern Territory. No jurisdiction...
Abstract Background Antiviral therapy for chronic hepatitis B (CHB) is effective and can substantially reduce the risk of progressive liver disease hepatocellular carcinoma but often administered an indefinite duration. Adherence has been shown in clinical trials to maximize benefit prevent development resistance, however optimal threshold predicting outcomes not identified. The aim this study was analyse adherence using medication possession ration (MPR) its relation virological a large...
African-Australians have a high prevalence of chronic hepatitis B (CHB) and an increased risk liver cancer (hepatocellular carcinoma, HCC) at younger age than other affected groups living with CHB. The prevention HCC-related mortality is possible timely diagnosis CHB, regular monitoring including surveillance appropriate treatment antiviral therapy. Currently, little known about how CHB understand their condition, the need for monitoring. There were 19 semi-structured interviews conducted...
Data from qualitative semi-structured interviews with 19 participants primary care settings were thematically analysed.Critical elements in providing clinical identified at an organisational and provider level. A supportive culture included leadership, a multidisciplinary team approach, community engagement cultural competency, while provider-related issues authorisation to prescribe, access linguistic mediators effective relationships relevant specialist services.The research practice...
To assess the capacity of COVID Positive Pathway, a collaborative model care involving Victorian public health unit, hospital services, primary care, community organisations, and North Western Melbourne Primary Health Network, to support people with coronavirus disease 2019 (COVID-19) isolating at home.Cohort study adults in northwest COVID-19, 3 August - 31 December 2020.Demographic clinical characteristics, social welfare needs cared for by tier level.Of 1392 referred Pathway 858 were...
Background Active follow-up of chronic hepatitis C notifications to promote linkage care is a promising strategy support elimination. Aim This pilot study in Victoria, Australia, explored if the Department Health could on cases through their diagnosing clinicians, assess and complete data missing from notification. Methods For received between 1 September 2021 31 March 2022 unspecified (i.e. acquired > 24 months ago or unknown duration), contact with clinicians was attempted. Data were...
With substantial SARS-CoV-2 transmission in the community, early oral antiviral access has become a pillar of our response Oral therapies for treatment mild to moderate coronavirus disease 2019 (COVID-19) are recommended Australian guidelines reduce risk serious illness, hospitalisation and mortality people who do not require oxygen have factors progression severe disease.1 treatments should be started within five days after onset symptoms, or as soon practical diagnosis an asymptomatic...
Objective To compare the concordance and acceptability of saliva testing with standard-of-care oropharyngeal bilateral deep nasal swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in children general practice. Design Prospective multicentre diagnostic validation study. Setting Royal Children's Hospital, two practices (cohealth, West Melbourne; Cirqit Health, Altona North) Melbourne, July–October 2020. Participants 1050 people who provided paired oropharyngeal-nasal swabs...
By learning from Australia's response to the pandemic and breaking down siloes, we can build a more integrated resilient health system The Australian care is well regarded on global stage in terms of balance between investment outcomes delivered, particularly universal access, quality safety.1 However, there considerable fragmentation poor coordination communication hospitals primary care, which limits further improvement.2, 3 Geographical barriers, workforce shortages issues relating...
Abstract Background Aboriginal and Torres Strait Islander people are disproportionately affected by hepatitis B virus (HBV) infection. A proposed mismatch between standard vaccines the HBV/C4 sub‐genotype prevalent in Northern Territory (NT) may reduce vaccine effectiveness. Aims To determine HBV prevalence NT Indigenous status to explore patterns of immunity following implementation universal vaccination, using a large longitudinal diagnostic dataset. Methods retrospective analysis all...
This study aimed to assess utilization of health-care services in people with decompensated cirrhosis (DC) or hepatocellular carcinoma (HCC) and a "late diagnosis" hepatitis B C.Hepatitis C cases during 1997-2016 Victoria, Australia, were linked hospitalizations, deaths, liver cancer diagnoses, medical services. A late diagnosis was defined as notification occurring after, at the same time, within 2 years preceding an HCC/DC diagnosis. Services provided 10-year period before assessed,...